1. A Multicenter Study of the Mid-term Outcomes of Patients with Uncomplicated Type B Aortic Dissection After Distal Porous Talos Stent-Graft Implantation.
- Author
-
Shu C, Fang K, Chen D, Liu X, Gao Y, Huang J, Zhang X, Qiao T, Dai X, Zhou W, Han T, Zhang X, Jiang W, Chen L, Luo M, and Li Q
- Subjects
- Humans, Male, Middle Aged, Female, Retrospective Studies, Treatment Outcome, Time Factors, Adult, Aged, Risk Factors, Porosity, Aortic Aneurysm surgery, Aortic Aneurysm diagnostic imaging, Aortic Aneurysm mortality, Postoperative Complications etiology, Japan, Aortic Dissection surgery, Aortic Dissection diagnostic imaging, Aortic Dissection mortality, Stents, Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation instrumentation, Blood Vessel Prosthesis Implantation adverse effects, Blood Vessel Prosthesis Implantation mortality, Prosthesis Design, Endovascular Procedures instrumentation, Endovascular Procedures adverse effects, Endovascular Procedures mortality
- Abstract
Background: The Talos stent-graft has extended length to improve aortic remodeling, and distal porous design to decrease the rate of spinal cord ischemia (SCI). This study retrospectively analyzed its mid-term outcomes for uncomplicated type B aortic dissection in a multicenter study., Methods: The primary safety end point was 30-day major adverse events, including all-cause mortality, dissection-related mortality, conversion to open surgery, and device-related adverse events. The primary efficacy end point was treatment success at 12 months postoperation, defined as no technical failure or secondary dissection-related reintervention. The survival status of the patients was visualized using the Kaplan-Meier curve. Aortic growth was assessed at 4 levels, and SCI was evaluated at 12 months., Results: 113 patients participated with a mean age of 54.4 (11.1) years and 71.7% (81/113) were male. The 30-day mortality was 0.9% (1/113), no conversions to open surgery or device-related adverse events were recorded. The 12-month treatment success rate was 99.1% (112/113), with no dissection-related reinterventions. There was no spinal cord or visceral ischemia at 12 months. At a median of 34 months follow-up, 9 further deaths were recorded and the 3-year survival rate was 91.7%. The percentage of aortic growth was 1.8% (2/111) at the tracheal bifurcation, 3.6% (4/111) below the left atrium, 6.0% (5/83) above the celiac artery, and 12.1% (9/74) below the lower renal artery. The total thrombosis rate of the false lumen at the stented segment was 80.5% (91/113)., Conclusions: The results showed satisfactory results of Talos stent-graft in terms of safety and efficacy. More data are needed to confirm the long-term performance., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF